Moderna raised its full-year 2026 revenue growth outlook to 15% to 25%, up from its previous guidance of up to 10%. The company reported the update on Friday after beating third-quarter revenue and earnings estimates.
Third-quarter revenue rose 29% to $1.31 billion. The company said $780 million came from the U.S. and $533 million from international markets. Moderna posted net income of $162 million, or 38 cents per share, compared with a net loss of $200 million, or 51 cents per share, a year earlier.
CEO Stéphane Bancel credited newer products and geographic diversification for the quarter. He said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. Bancel also said Moderna's stand-alone flu shot, approved in the U.S. in August, will have a "limited launch" in the country in 2026 because of timing. He said expansion in Canada, the U.K. and Asia helped results, and that lower costs contributed to the profit.
Shares rose roughly 3% in premarket trading on Friday. The stock has risen more than 700% this year, which the report links to optimism about the company's potential cancer vaccine.
Bancel described the market's reaction to recent data on the personalized cancer vaccine, developed with Merck and used with Keytruda in certain melanoma patients, as "surprising." Part of that data leaked on social media days before investigators were set to present it at a European medical conference, and investors sold the stock after the leak. Bancel said long-term investors, analysts and doctors responded positively to the full data.